UNITED STATES
                      SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                             ----------------------

                                    FORM 10-Q

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
    ACT OF 1934

For the quarterly period ended December 31, 2010

                                            or

[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
    ACT OF 1934

For the transition period from ____________________ to _______________________


COMMISSION FILE NO. 0-10581

                             ----------------------

                                 TRIMEDYNE, INC.
                                 ---------------
             (Exact Name of Registrant as Specified in its Charter)

           NEVADA                                               36-3094439
           ------                                               ----------
(STATE OR OTHER JURISDICTION                                 (I.R.S. EMPLOYER
     OF INCORPORATION)                                      IDENTIFICATION NO.)

        25901 COMMERCENTRE DRIVE                                  92630
        LAKE FOREST, CALIFORNIA                                 (ZIP CODE)
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES)

               Registrant's Telephone Number, Including Area Code:

                                 (949) 951-3800

                             ----------------------

           Securities Registered Pursuant to Section 12(b) of the Act:
                                      NONE

           Securities Registered Pursuant to Section 12(g) of the Act:
                     Common Stock, $.01 Par Value per Share
                                (Title of Class)

                             ----------------------

Indicate by check mark whether the registrant (1) has filed all reports to be
filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the
preceding 12 months (or for such shorter period that the registrant was required
to file such reports) and (2) has been subject to such filing requirements for
the past 90 days.  Yes [X] No [_]

Indicate by check mark whether the registrant has submitted electronically and
posted on its corporate Web site, if any, every Interactive Data File required
to be submitted and posted pursuant to Rule 405 of Regulation S-T (ss. 232.405
of this chapter) during the preceding 12 months (or for such shorter period that
the registrant was required to submit and post such files). Yes [ ] No [_]

Indicate by check mark whether the registrant is a large accelerated filer, an
accelerated filer, a non-accelerated filer or a smaller reporting company. See
definitions of "large accelerated filer," "accelerated filer" and "smaller
reporting company" in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer  |_|               Accelerated filer         |_|
Non-accelerated filer    |_|               Smaller reporting company |X|

Indicate by check mark whether the registrant is a shell company (as defined in
Rule 12b-2 of the Exchange Act of 1934). Yes [ ] No [X]

As of February 18, 2011, there were outstanding 18,365,960 shares of
registrant's Common Stock.





                                 TRIMEDYNE, INC.

                                                                     Page Number
                                                                     -----------

PART I.          Financial Information                                     3

        ITEM 1.  Financial Statements (Unaudited)

                 Condensed Consolidated Balance Sheets                     3

                 Condensed Consolidated Statements of Operations           4

                 Condensed Consolidated Statements of Cash Flows           5

                 Notes to Condensed Consolidated Financial Statements      6

        ITEM 2.  Management's Discussion and Analysis of Financial
                 Condition and Results of Operations                       12

        ITEM 3.  Quantitative and Qualitative Disclosures About Market
                 Risk - N/A                                                14

        ITEM 4. Controls and Procedures                                    14

PART II.         Other Information                                         15

        ITEM 1.  Legal Proceedings                                         15

        ITEM 1A. Risk Factors - N/A                                        15

        ITEM 2. Unregistered Sales of Equity Securities and Use of
                Proceeds                                                   15

        ITEM 3. Defaults Upon Senior Securities                            15

        ITEM 4. [Removed and Reserved]                                     15

        ITEM 5. Other Information                                          15

        ITEM 6. Exhibits                                                   15

SIGNATURES                                                                 16


                                        2






     
                                                TRIMEDYNE, INC.
                                     CONDENSED CONSOLIDATED BALANCE SHEETS
                                                  (UNAUDITED)


                                   ASSETS
                                                                  December 31, 2010         September 30, 2010
                                                                  ------------------        ------------------

Current assets:
  Cash and cash equivalents                                       $        2,353,000        $        2,528,000
  Trade accounts receivable, net of allowance
    for doubtful accounts of $12,000 at December 31, 2010
    and September 30, 2010                                                   741,000                   691,000
  Inventories                                                              2,471,000                 2,613,000
  Other current assets                                                       221,000                   177,000
                                                                  ------------------        ------------------
      Total current assets                                                 5,786,000                 6,009,000

Property and equipment, net                                                  855,000                   908,000
Other                                                                         98,000                   102,000
Goodwill                                                                     544,000                   544,000
                                                                  ------------------        ------------------
    Total Assets                                                  $        7,283,000        $        7,563,000
                                                                  ==================        ==================

                      LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:
  Accounts payable                                                $          200,000        $          129,000
  Accrued expenses                                                           586,000                   588,000
  Deferred revenue                                                            61,000                    75,000
  Accrued warranty                                                            23,000                    17,000
  Income tax payable                                                          13,000                    11,000
  Current portion of note payable and capital leases                         127,000                   161,000
  Accrued interest due to related party                                       11,000                     3,000
                                                                  ------------------        ------------------
    Total current liabilities                                              1,021,000                   984,000

Senior secured convertible note to related party,
 net of discount of $94,000 and $99,000, respectively                        406,000                   401,000
Note payable and capital leases, net of current portion                       71,000                    92,000
Deferred rent                                                                 83,000                    80,000
Derivative liabilities                                                        81,000                    96,000
                                                                  ------------------        ------------------

    Total liabilities                                                      1,662,000                 1,653,000
                                                                  ------------------        ------------------
Commitments and contingencies

Stockholders' equity:
  Preferred stock - $0.01 par value, 1,000,000 shares
    authorized, none issued and outstanding                                       --                        --
  Common stock - $0.01 par value, 30,000,000 shares authorized,
    18,467,569 shares issued at December 31, 2010 and
    September 30, 2010, 18,365,960 shares outstanding at
    December 31, 2010 and September 30, 2010                                 186,000                   186,000
  Additional paid-in capital                                              51,242,000                51,238,000
  Accumulated deficit                                                    (45,094,000)              (44,801,000)
                                                                  ------------------        ------------------
                                                                           6,334,000                 6,623,000
  Treasury stock, at cost (101,609 shares)                                  (713,000)                 (713,000)
                                                                  ------------------        ------------------

   Total stockholders' equity                                              5,621,000                 5,910,000
                                                                  ------------------        ------------------

   Total liabilities and stockholder's equity                     $        7,283,000        $        7,563,000
                                                                  ==================        ==================


                     See accompanying notes to condensed consolidated financial statements


                                                       3





                                 TRIMEDYNE, INC.
                 CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
                                   (UNAUDITED)

                                                    For the Three Months Ended
                                                           December 31,

                                                         2010           2009
                                                    ------------   ------------
Net revenues                                        $  1,635,000   $  1,654,000
Cost of revenues                                       1,026,000      1,076,000
                                                    ------------   ------------
  Gross profit                                           609,000        578,000

Operating expenses:
 Selling, general and administrative                     707,000        629,000
 Research and development                                210,000        305,000
                                                    ------------   ------------
   Total operating expenses                              917,000        934,000
                                                    ------------   ------------

(Loss) from operations                                  (308,000)      (356,000)

Other income, net                                         17,000         61,000
                                                    ------------   ------------

(Loss) before income taxes                              (291,000)      (295,000)

Provision for income taxes                                 2,000          5,000
                                                    ------------   ------------

Net (loss)                                          $   (293,000)  $   (300,000)
                                                    ============   ============

Net (loss) per share:

  Basic                                             $      (0.02)  $      (0.02)
                                                    ============   ============
  Diluted                                           $      (0.02)  $      (0.02)
                                                    ============   ============

Weighted average number of shares outstanding:

   Basic                                              18,365,960     18,365,960
                                                    ============   ============
   Diluted                                            18,365,960     18,365,960
                                                    ============   ============


      See accompanying notes to condensed consolidated financial statements

                                        4






                                           TRIMEDYNE, INC.
                           CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
                                             (UNAUDITED)


                                                                             Three Months Ended
                                                                                December 31,
                                                                              2010          2009
                                                                          -----------   -----------
Cash flows from operating activities:
Net loss                                                                     (293,000)     (300,000)
   Adjustments to reconcile net loss to net cash
   used in operating activities:
      Stock-based compensation                                                  4,000         6,000
      Depreciation and amortization                                            63,000        78,000
      Amortization of debt discount                                             5,000            --
      Change in fair value of derivative liabilities                          (15,000)           --
      Loss on disposal of fixed assets                                          2,000            --
      Changes in operating assets and liabilities:
        Trade accounts receivable                                             (50,000)       52,000
        Inventories                                                           142,000      (310,000)
        Other assets                                                          (40,000)       90,000
        Accounts payable                                                       71,000       (22,000)
        Accrued expenses                                                       (2,000)       16,000
        Accrued interest to related party                                       8,000            --
        Income tax payable                                                      2,000         5,000
        Deferred revenue                                                      (14,000)           --
        Accrued warranty                                                        6,000       (5,000)
        Deferred rent                                                           3,000       (9,000)
                                                                          -----------   -----------

      Net cash used in operating activities                                  (108,000)     (399,000)
                                                                          -----------   -----------

Cash flows from investing activities:
   Purchase of property and equipment                                         (12,000)      (25,000)
                                                                          -----------   -----------
      Net cash used in investing activities                                   (12,000)      (25,000)
                                                                          -----------   -----------

Cash flows from financing activities:

   Principal payments on notes payable and capital leases                     (55,000)      (66,000)
                                                                          -----------   -----------

     Net cash used in financing activities                                    (55,000)      (66,000)
                                                                          -----------   -----------

Net decrease in cash and cash equivalents                                    (175,000)     (490,000)
Cash and cash equivalents at beginning of period                            2,528,000     1,621,000
                                                                          -----------   -----------
Cash and cash equivalents at end of period                                $ 2,353,000   $ 1,131,000
                                                                          ===========   ===========


Supplemental disclosure of cash flow information:

No cash was paid for income taxes during the three months ended December 31,
2010 and 2009. Cash paid for interest during the three months ended December 31,
2010 and 2009 was approximately $10,000 and $10,000, respectively.


      See accompanying notes to condensed consolidated financial statements

                                        5





                                 TRIMEDYNE, INC.
              NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
                           DECEMBER 31, 2010
                               (UNAUDITED)

NOTE 1 - Summary of Significant Accounting Policies

Principles of Consolidation

The accompanying condensed consolidated financial statements include the
accounts of Trimedyne, Inc., a Nevada corporation, its wholly owned subsidiary,
Mobile Surgical Technologies, Inc. ("MST"), a Texas corporation, and its 90%
owned inactive subsidiary, Cardiodyne, Inc. ("Cardiodyne"), a Nevada
corporation, (collectively, the "Company"). All intercompany accounts and
transactions have been eliminated in consolidation.

Management's Plans

We are about to introduce a new line of Single Use optical fibers to supplement
our line of Reusable optical fibers. These optical fibers are used with our
Holmium lasers and Holmium lasers with compatible connectors made by others for
the fragmentation of urinary stones in the kidney, ureter and bladder and
biliary stones in the gall bladder. Many hospitals in the United States and
other developed countries prefer having a new, sterile optical fiber for each
stone case, rather than having to clean, clip and re-sterilize a reusable
optical fiber after each case.

We are exploring various avenues to reduce our cost of manufacturing Lasers,
expand the distribution of our products, particularly our new VaporMAX Side
Firing Fiber and Single Use Optical Fibers, to increase our revenues and improve
our profit margins. We are continuing to seek licensees of our patents and
proprietary technologies. There is, of course, no assurance that these efforts
will be successful.

We believe that existing cash flows are sufficient to fund operations through
December 31, 2011; however, we have incurred losses from operations for the past
three years. There can be no assurance that we will be able to maintain or
achieve sales growth in the next 12 months, or that the Company will be
profitable. Thus, it is possible that additional working capital in the next 12
months may be required. If necessary, we will raise additional debt and/or
equity capital, sell some of our assets, reduce our costs by eliminating certain
personnel positions and reducing certain overhead costs in order to fund
operations. There is no assurance that our efforts to do so will be successful.

Unaudited Interim Financial Information

The accompanying unaudited condensed consolidated financial statements have been
prepared by the Company in accordance with accounting principles generally
accepted in the United States of America for interim financial information, and
pursuant to the instructions to Form 10-Q promulgated by the Securities and
Exchange Commission ("SEC"). Accordingly, they do not include all information
and disclosures required by generally accepted accounting principles for
complete financial statement presentation. In the opinion of management, the
accompanying condensed consolidated financial statements contain all adjustments
(consisting of only normal recurring adjustments) necessary to present fairly
the Company's consolidated financial position as of December 31, 2010 and the
results of its operations and its cash flows for the three months ended December
31, 2010 and 2009. Results for the three months ended December 31, 2010 are not
necessarily indicative of the results to be expected for the year ending
September 30, 2011.

While management believes that the disclosures presented are adequate to make
the information not misleading, it is suggested that these condensed
consolidated financial statements be read in conjunction with the condensed
consolidated financial statements and the notes included in the Company's 2010
annual report on Form 10-K for the year ended September 30, 2010.

Stock-Based Compensation

The fair value of stock-based awards is calculated using the Black-Scholes
option pricing model. The Black-Scholes model requires subjective assumptions
regarding future stock price volatility and expected time to exercise, which
greatly affect the calculated values. The expected term of options granted is
derived from historical data on employee exercises and post-vesting employment
termination behavior. The risk-free rate selected to value any particular grant
is based on the U.S. Treasury rate that corresponds to the pricing term of the
grant effective as of the date of the grant. The expected volatility is based on
the Company's historical volatilities of its common stock. These factors could
change in the future, affecting the determination of stock-based compensation
expense in future periods. During the three months ended December 31, 2010,
there were no stock options granted.

As of December 31, 2010, there was approximately $27,078 of total unrecognized
compensation cost, net of estimated expected forfeitures, related to employee
and director stock option compensation arrangements. This unrecognized cost is
expected to be recognized on a straight-line basis over the next three years.

The following table summarizes stock-based compensation expense related to
employee and director stock options under Accounting Standards Codification
("ASC") No. 718 Stock Compensation for the three months ended December 31, 2010
and 2009, which was allocated as follows:


     
                                                             Three Months Ended
                                                    December 31, 2010     December 31, 2009
                                                       (Unaudited)
                                                    -----------------     -----------------
Stock-based compensation included in:
   Cost of revenues                                     $  1,000           $  1,000
   Research and development expenses                    $  1,000           $  1,000
   Selling, general, and administrative expenses        $  2,000           $  4,000



                                        6



NOTE 2 - Composition of Certain Balance Sheet Captions

Inventories, net of reserves, consist of the following:

                                            December 31,  September 30,
                                                2010          2010
                                            (Unaudited)
                                            -----------   ------------
   Raw materials                            $   908,000    $   885,000
   Work-in-process                              718,000        635,000
   Finished goods                               845,000      1,093,000
                                            -----------   ------------
                                            $ 2,471,000    $ 2,613,000
                                            ===========   ============


For the three months ended December 31, 2010 and 2009, the aggregate net
realizable value of demonstration and evaluation lasers did not comprise a
material amount in inventories.

Other current assets consist of the following:

                                                    December 31,   September 30,
                                                       2010            2010
                                                    (Unaudited)
                                                    -----------    ------------
   Royalty receivable                               $    19,000    $     61,000
   Prepaid insurance                                     38,000          55,000
   Prepaid income tax                                    87,000           4,000
   Prepaid Rent                                          26,000          26,000
   Short-term deposits                                   33,000           8,000
   Other                                                 18,000          23,000

                                                    -----------    ------------
   Total other current assets                       $   221,000    $    177,000
                                                    ===========    ============

Property and equipment consist of the following:

                                                    December 31,   September 30,
                                                       2010            2010
                                                    (Unaudited)
                                                    -----------    ------------
   Furniture and equipment                          $ 3,384,000    $  3,377,000
   Leasehold improvements                               643,000         643,000
   Other                                                244,000         244,000
                                                   ------------    ------------
                                                      4,271,000       4,264,000
Less accumulated depreciation and amortization       (3,416,000)     (3,356,000)
                                                   ------------    ------------
   Total property and equipment                    $    855,000     $   908,000
                                                   ============    ============

Accrued expenses consist of the following:

                                                   December 31,  September 30,
                                                       2010            2010
                                                   (Unaudited)
                                                   ------------  -------------
   Accrued vacation                                 $   176,000    $   169,000
   Accrued salaries and wages                            94,000         78,000
   Sales and use tax                                     65,000         63,000
   Accrued legal                                             --        175,000
   Customer deposits                                    163,000          6,000
   Accrued commissions                                   62,000         79,000
   Accrued payroll taxes                                 13,000          3,000
   Other                                                 13,000         15,000
                                                    -----------    -----------
   Total accrued expenses                           $   586,000    $   588,000
                                                    ===========    ===========

                                        7



NOTE 3 - Convertible Note Payable to Related Party, Notes Payable and Capital
Leases

Senior Secured Convertible Note Payable to Related Party

On August 20, 2010, Marvin P. Loeb, the Company's Chairman and CEO, loaned the
Company $500,000 evidenced by a 6% Senior Secured Convertible Note with a
principal amount of $500,000 (the "Note"), which is secured by all of the assets
of the Company, and is due August 19, 2015. However, the Note contained a
provision whereby the CEO can redeem the note at any time. The CEO agreed not to
redeem the Note, without the written consent of the Company, for a period of two
years from September 30, 2010. Thus, the Note is reflected as a long-term
obligation as of December 31, 2010 on the accompanying consolidated balance
sheet. The funds provided under the Note are to be used for operations.

The Note can be converted at any time into shares of the Company's common stock
at a conversion price of $0.21 per share. The conversion price equaled the fair
market value of the Company's common stock on the date of the purchase of the
Note, and thus no beneficial conversion feature was recorded. However, the Note
contains an anti-dilution provision whereby the price resets in the event of the
sale or issuance of shares at a price lower than the conversion price
set forth in the Note. Thus, the Company determined that this provision caused
the conversion feature to be bifurcated from the Note and treated as a
derivative and accounted for at its fair value. The Company will revalue the
derivative at each reporting period.

At September 30, 2010, management determined the fair market value of the
conversion feature was $94,000 and recorded the offset as a discount to the
Note. At December 31, 2010, management determined the fair market value of the
conversion feature was $80,000, resulting in a gain on change in derivative
liability of $14,000.



                                        8




The Company estimated the fair value of the conversion feature using the Lattice
model. Accordingly, the fair value of the conversion feature as determined using
the Lattice model is affected by our stock price on the date of issuance as well
as assumptions regarding a number of complex and subjective variables. These
variables include, but are not limited to, our expected stock price volatility
over the term of the Notes, actual and projected redemptions and conversion
price resets.

Expected volatility is based primarily on historical volatility. Historical
volatility was computed using daily pricing observations for recent periods that
correspond to expected remaining life of the Notes. We believe this method
produces an estimate that is representative of our expectations of future
volatility over the expected term of this conversion feature. We currently have
no reason to believe future volatility over the expected remaining life of the
conversion feature is likely to differ materially from historical volatility.
Volatility used in the calculation ranged from a low of 124% in year one to a
high of 301% in year five. Management estimated that the probability of the Note
being redeemed 0% increasing by 10% per quarter.

The Company is amortizing the discount over the period of two years, the term of
the CEO's commitment not to call the Note, using the effective interest method.
During the three months ended December 31, 2010, the Company amortized $5,000 of
the discount to interest expense. As of December 31, 2010, the unamortized
discount is $94,000.

NOTE 3 - Notes Payable and Capital Leases

     

Notes payable and capital leases consists of the following at December 31, 2010 and September 30, 2010:

                                                                                     December 31,   September 30,
                                                                                         2010           2010
                                                                                     (Unaudited)
                                                                                     -----------    ------------
Capital lease agreement in connection with the purchasing of equipment bearing
an effective interest rate of 8.69% per annum. The lease requires monthly
payments of $3,147 through September 2012.                                           $    27,000     $   37,000

Capital lease agreement in connection with the purchasing of equipment bearing
an effective interest rate of 9.25% per annum. The lease requires monthly
payments of $4,979 through January 2013.                                                 109,000        121,000

Capital lease agreement in connection with the purchasing of equipment
bearing an effective interest rate of 9.23% per annum. The lease requires
monthly payments of $526 through February 2013.                                           12,000         14,000

Capital lease agreement in connection with the purchasing of equipment bearing
an effective interest rate of 8.82% per annum. The lease requires monthly
payments of $2,403 through March 2012.                                                    34,000         38,000

Capital lease agreement in connection with the purchasing of ERP software
bearing an effective interest rate of 8.51% per annum. The lease requires
monthly payments of $3,195 through April 2011.                                            10,000         19,000

Finance agreement issued in connection with the purchasing of certain insurance
policies. The note bears interest at 4.7% per annum and require monthly
principal and interest payments of $6,042 through January 2011.                            6,000         24,000
                                                                                      -----------     ----------
                                                                                     $   198,000     $  253,000

Less:  current portion                                                                  (127,000)      (161,000)
                                                                                     -----------     ----------
                                                                                     $    71,000     $   92,000
                                                                                     ===========     ==========


NOTE 5 - Commitments and Contingencies

Litigation

We are subject to various claims and actions that arise in the ordinary course
of business. The litigation process is inherently uncertain, and it is possible
that the resolution of any future litigation may adversely affect us.

The Company had no product liability lawsuits commenced against it during the
three months ended December 31, 2009 and 2010. The Company has insurance to
cover product liability claims. This insurance provides the Company with
$5,000,000 of coverage for each occurrence with a general aggregate coverage of
$5,000,000. Trimedyne's liability is limited to a maximum of $25,000 per
occurrence unless the judgment against the Company exceeds the $5,000,000
insurance coverage. In such case, Trimedyne would be liable for any liability in
excess of $5,000,000.

To avoid the cost and uncertainty of litigation, on November 24, 2010, we
settled the lawsuit filed against us and others by CardioFocus. We paid
CardioFocus $175,000,entered into mutual releases and the lawsuit was dismissed.
This settlement expense was accrued and included in other expense for the year
ended September 30, 2010 and paid during the three months ended December 31,
2010.

                                        9





Guarantees and Indemnities

The Company has made certain indemnities and guarantees, under which it may be
required to make payments to a guaranteed or indemnified party. The Company
indemnifies its directors, officers, employees and agents to the maximum extent
permitted under the laws of the State of California. In connection with its
facility leases, the Company has indemnified its users of lasers for certain
claims arising from the use of the lasers. The duration of the guarantees and
indemnities varies, and in many cases is indefinite. These guarantees and
indemnities do not provide for any limitation of the maximum potential future
payments the Company could be obligated to make. Historically, the Company has
not been obligated to make any payments for these obligations and no liabilities
have been recorded for these indemnities and guarantees in the accompanying
condensed consolidated balance sheet.

Risks and Uncertainties

The Centers for Medicare and Medicaid Services (CMS), the agency of the U.S.
Government that administers the Medicare Program, does not reimburse for thermal
intradiscal procedures to treat spinal discs including the use of the Company's
pulsed Holmium Lasers. Since most people suffering from a herniated or ruptured
spinal disc are below Medicare age, we do not believe CMS's decision will have
an adverse impact on our business.

NOTE 7 - Segment Information

The Company's segments consist of individual companies managed separately with
each manager reporting to the Chief Executive Officer. Revenues, and operating
or segment profit, are reflected net of inter-segment sales and profits. Segment
profit is comprised of net sales less operating expenses. Other income and
expense and income taxes are not allocated and reported by segment since they
are excluded from the measure of segment performance reviewed by management.

Data with respect to these operating activities for the three months ended
December 31, 2010 and 2009 are as follows:


     
                                            For the Three Months Ended                       For the Three Months Ended
                                                 December 31, 2010                                 December 31, 2009
                                                   (Unaudited)
                                                     Service and                                      Service and
                                        Products        Rental        Total             Products        Rental          Total
                                      ---------------------------------------         -----------------------------------------

   Revenue                            $   929,000   $   706,000   $ 1,635,000         $   951,000   $    703,000    $ 1,654,000
   Cost of sales                          611,000       415,000     1,026,000             682,000        394,000      1,076,000
                                      ---------------------------------------         -----------------------------------------

   Gross profit                           318,000       291,000       609,000             269,000        309,000        578,000

   Expenses:
   Selling, general and
     administrative                       529,000       178,000       707,000             462,000        167,000        629,000
   Research and development               210,000            --       210,000             305,000             --        305,000
                                      ---------------------------------------         -----------------------------------------

   Income (loss) from operations      $  (421,000)  $   113,000      (308,000)        $  (498,000)  $    142,000       (356,000)
                                      =========================                       ==========================
   Other:
     Interest income                                                    1,000                                               --
     Interest expense                                                 (18,000)                                          (10,000)
     Royalty income                                                    19,000                                            68,000
     Change in fair market value of derivative liabilities             15,000                                                --
     Other income                                                          --                                             3,000
     Provision for income tax                                          (2,000)                                           (5,000)
                                                                  -----------                                       -----------
   Net loss                                                       $  (293,000)                                      $  (300,000)
                                                                  ===========                                       ===========


Sales and gross profit to customers by similar products and services for the
three months ended December 31, 2010 and 2009 were as follows:

                                           For the Three Months
                                            Ended December 31,
                                             2010         2009
                                          (Unaudited)
                                          ----------   ----------
By similar products and services:
Revenues:
  Laser equipment and accessories         $  256,000   $  261,000
  Delivery and disposable devices            673,000      690,000
  Service and rental                         706,000      703,000
                                          ----------   ----------
        Total                             $1,635,000   $1,654,000
                                          ==========   ==========


                                        10




Gross profit
  Laser equipment and accessories         $   15,000   $   15,000
  Delivery and disposable devices            303,000      254,000
  Service and rental                         291,000      309,000
                                          ----------   ----------
        Total                             $  609,000   $  578,000
                                          ==========   ==========

Sales in foreign countries for the three months ended December 31, 2010 and 2009
accounted for approximately 23% and 18%, respectively, of the Company's total
sales. The breakdown by geographic region is as follows:


                        Three Months Ended     Three Months Ended
                        December 31, 2010      December 31, 2009
                           (Unaudited)
                        -----------------      -----------------
Asia                    $         276,000      $         132,000
Europe                             40,000                 62,000
Latin America                      44,000                 14,000
Australia                          11,000                 89,000
Middle East                         8,000                  3,000
Other                                  --                  2,000
                        -----------------      -----------------
                        $         379,000      $         302,000
                        =================      =================

All long-lived assets were located in the United States during the three months
ended December 31, 2010 and 2009 with the exception of one laser located in
Canada. Total segment assets at December 31, 2010 and 2009 for the Products
segment were $5,714,000 and $4,841,000, respectively, and for the Service and
Rental segment were $1,547,000 and $1,663,000, respectively. Total segment
assets differ from total assets on a consolidated basis as a result of
unallocated corporate assets primarily comprised of immaterial amounts of
property and equipment, etc.


                                        11







ITEM 2.  MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
         AND RESULTS OF OPERATIONS

FORWARD-LOOKING STATEMENTS

This information should be read in conjunction with the condensed consolidated
financial statements and notes thereto included in Item 1 of Part I of this
Quarterly Report and the audited consolidated financial statements and notes
thereto and Management's Discussion and Analysis of Financial Condition and
Results of Operations for the year ended September 30, 2010 contained in our
2010 Annual Report on Form 10-K.

The statements contained in this Quarterly Report on Form 10-Q that are not
historical facts may contain forward-looking statements that involve a number of
known and unknown risks and uncertainties that could cause actual results to
differ materially from those discussed or anticipated by management. Potential
risks and uncertainties include, among other factors, general business
conditions, government regulations governing medical device approvals and
manufacturing practices, competitive market conditions, success of the Company's
business strategy, delay of orders, changes in the mix of products sold,
availability of suppliers, concentration of sales in markets and to certain
customers, changes in manufacturing efficiencies, development and introduction
of new products, fluctuations in margins, timing of significant orders, and
other risks and uncertainties currently unknown to management. We do not
undertake any duty to update forward-looking statements after the date they are
made or to conform them to actual results or to changes in circumstances or
expectations.

OVERVIEW

Trimedyne, Inc. (the "Company", "we", "our" or "us") is engaged in the
development, manufacturing and marketing of 80 and 30 watt Holmium "cold" pulsed
lasers ("Lasers") and a variety of disposable and reusable, fiber optic laser
energy delivery devices ("Fibers", "Needles" and "Tips") for use in a broad
array of medical applications.

Our Lasers, Fibers, Needles and Tips have been cleared for sale by the U.S. Food
and Drug Administration for use in orthopedics, urology, ear, nose and throat
surgery, gynecology, gastrointestinal surgery, general surgery and other medical
specialties. Many of the medical procedures in which our Lasers, Fibers, Needles
and Tips are used are being reimbursed by Medicare and many insurance companies
and health plans.

Our 100% owned subsidiary, Mobile Surgical Technologies, Inc. ("MST"), is
engaged in the rental of lasers, along with the services of a trained operator
and, if requested, the provision of applicable Fibers, Needles or Tips, on a
"fee per case" basis to hospitals, surgery centers, group practices and
individual physicians in Texas and nearby areas.

The principal market for our Lasers and Side Firing Needles is presently in
orthopedics to treat herniated (bulging) and ruptured lumbar, thoracic and
cervical discs in the spine, two of the four major causes of lower back, neck
and leg pain, typically on an outpatient basis. Our Lasers and Tips are also
used in orthopedics to treat damage in joints, such as the knee, shoulder,
elbow, hip, ankle and wrist, in outpatient, arthroscopic procedures.

The Company's Lasers and Fibers are also used in Urology to fragment stones in
the Kidney, ureter or bladder. The Company's new VaporMAX(R) Side Firing Optical
Fiber device is also used to vaporize a portion of the male prostate to treat
benign prostate hyperplasia of "BPH", commonly referred to as an "enlarged
prostate."

CRITICAL ACCOUNTING POLICIES

Revenue Recognition

We prepare our consolidated financial statements in accordance with accounting
principles generally accepted in the United States of America. The preparation
of these financial statements require the use of estimates and assumptions that
affect the reported amounts of assets and liabilities and the disclosure of
contingent assets and liabilities at the date of the financial statements and
the reported amount of revenues and expenses during the reporting period. Our
management periodically evaluates the estimates and judgments made. Management
bases its estimates and judgments on historical experience and on various
factors that are believed to be reasonable under the circumstances. Actual
results may differ from these estimates as a result of different assumptions or
conditions.


                                        12




The methods, estimates, and judgment we use in applying our most critical
accounting policies have a significant impact on the results we report in our
financial statements. The SEC has defined "critical accounting policies" as
those accounting policies that are most important to the portrayal of our
financial condition and results, and require us to make our most difficult and
subjective judgments, often as a result of the need to make estimates of matters
that are inherently uncertain. Based upon this definition, our most critical
estimates relate to the fair value of warrant liabilities. We also have other
key accounting estimates and policies, but we believe that these other policies
either do not generally require us to make estimates and judgments that are as
difficult or as subjective, or it is less likely that they would have a material
impact on our reported results of operations for a given period. For additional
information see Note 2, "Summary of Significant Accounting Policies" in the
notes to our reviewed financial statements appearing elsewhere in this quarterly
report and our annual audited financial statements appearing on Form 10-K.
Although we believe that our estimates and assumptions are reasonable, they are
based upon information presently available, and actual results may differ
significantly from these estimates.

RESULTS OF OPERATIONS

Method of Presentation

The unaudited condensed consolidated financial statements include the accounts
of Trimedyne, Inc., its wholly owned subsidiary Mobile Surgical Technologies,
Inc. ("MST") and its 90% owned subsidiary, Cardiodyne.

Quarter ended December 31, 2010 compared to quarter ended December 31, 2009

During the quarter ended December 31, 2010, net revenues were $1,635,000 as
compared to $1,654,000 for the same period of the previous year, a $19,000 or
1.2% decrease. Net sales from lasers and accessories decreased by $5,000 or
1.9% to $256,000 during the three months ended December 31, 2010 from $261,000
in the same period of the prior year. Net sales from delivery and disposable
devices decreased by $17,000 or 2.5% to $673,000 in the current quarter from
$690,000 in the same quarter of the prior year. Net sales from service and
rental increased by $3,000 or 0.4% to $706,000 from $703,000 for the same
quarters.

Cost of sales during the quarter ended December 31, 2010 was 62.8% of net
revenue as compared to 65.1% of net revenues for the prior year quarter. Gross
profit from the sale of lasers and accessories was 5.9% as compared to 5.7% of
net revenues for the prior year three-month period. Gross profit from the sale
of delivery and disposable devices was 45.0% as compared to 36.8% for the prior
year period. The increase in gross profit during the the current quarter ended
December 31, 2010 was primarily due to cost reductions resulting from the
reduction of manufacturing staff and less material scrapped due to increased
efficiencies in manufacturing. Gross profit from revenue received from service
and rentals was 41.2% in the current quarter, as compared to 43.9% for the prior
three-month period. The reduction in gross profit for service and rentals was
primarily due to periodic repairs and maintenance for the laser fleet and
equipment utilized by MST.

Selling, general and administrative expenses increased in the current quarter to
$707,000 from $629,000 in the prior year quarter, an increase of $78,000 or
12.4%. The increase in selling, general and administrative expenses was
primarily the result of increases of $59,000 in legal expense and $41,000 in
marketing expense, offset by decreases of $17,000 in commissions expense, and
$9,000 in insurance expense.

Research and development expenditures for the quarter ended December 31, 2010,
decreased $95,000 or 3.0% to $210,000 as compared to $305,000 in the quarter
ended December 31, 2009. This decrease was a result the Company decreasing its
product development efforts and staff as it completed the development of its new
VaporMAX(TM) Side-Firing Device.

Other income, net decreased by $44,000 or 72.1% to $17,000 in the first quarter
ended December 31, 2010 from $61,000 in the first quarter of the prior year,
primarily due to a $49,000 reduction in royalty income received from Lumenis.
Other income during the quarter ended December 31, 2010 primarily consisted of
$19,000 of royalty income and $15,000 resulting from the change in fair market
value of derivative liabilities, offset by $18,000 in interest expense. Other
income during the quarter ended December 31, 2009 primarily consisted of $68,000
in royalty income offset by $10,000 in interest expense.

To avoid the cost and uncertainty of litigation, we settled the lawsuit filed
against us and others by CardioFocus. We paid CardioFocus $175,000,entered into
mutual releases and the lawsuit was dismissed. This settlement expense was
accrued and included in other expense for the year ended September 30, 2010.

For the current quarter, the Company had a net loss of $293,000 or $0.02 per
share, based on 18,365,960 basic weighted average number of common shares
outstanding, as compared to net loss of $300,000, or $0.02 per share, based on
18,365,960 basic weighted average number of common shares outstanding in the
same quarter of the previous year.

                                        13





Liquidity and Capital

At December 31, 2010, the Company had working capital of $4,765,000 compared to
$5,025,000 at the end of the fiscal year ended September 30, 2010. Cash
decreased by $175,000 to $2,353,000 from $2,528,000 at the fiscal year ended
September 30, 2010. During the three month period ended December 31, 2010, net
cash used in operating activities was $108,000. Net cash used in investing
activities was $12,000 for the purchase of equipment. Net cash used in financing
activities during the same three month period was $55,000, which was the result
of payments on debt incurred for the servicing of loans for equipment and
certain insurance policies.

We are about to introduce a new line of Single Use optical fibers to supplement
our line of Reusable optical fibers. These optical fibers are used with our
Holmium lasers and Holmium lasers with compatible connectors made by others for
the fragmentation of urinary stones in the kidney, ureter and bladder and
biliary stones in the gall bladder. Many hospitals in the United States and
other developed countries prefer having a new, sterile optical fiber for each
stone case, rather than having to clean, clip and re-sterilize a reusable
optical fiber after each case.

We are exploring various avenues to reduce our cost of manufacturing Lasers,
expand the distribution of our products, particularly our new VaporMAX Side
Firing Fiber and Single Use Optical Fibers, to increase our revenues and improve
our profit margins. We are continuing to seek licensees of our patents and
proprietary technologies. There is, of course, no assurance that these efforts
will be successful.

We believe that existing cash flows are sufficient to fund operations through
December 31, 2011; however, we have incurred losses from operations for the past
three years. There can be no assurance that we will be able to maintain or
achieve sales growth in the next 12 months, or that the Company will be
profitable. Thus, it is possible that additional working capital in the next 12
may be required. If necessary, we will raise additional debt and/or equity
capital, sell some of our assets, reduce our costs by eliminating certain
personnel positions and reducing certain overhead costs in order to fund
operations. There is no assurance that our efforts to do so will be successful.

OFF BALANCE SHEET ARRANGEMENTS

None.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK. N/A

ITEM 4. CONTROLS AND PROCEDURES

Disclosure Controls and Procedures. Our management has evaluated, under the
supervision and with the participation of our chief executive officer and
principal financial officer, the effectiveness of our disclosure controls and
procedures as of the end of the period covered by this report pursuant to Rule
13a-15(b) under the Securities Exchange Act of 1934 (the "Exchange Act"). Based
on that evaluation, our chief executive officer and principal financial officer
have concluded that, as of the end of the period covered by this report, our
disclosure controls and procedures are effective in ensuring that information
required to be disclosed in our Exchange Act reports is (1) recorded, processed,
summarized and reported in a timely manner, and (2) accumulated and communicated
to our management, including our chief executive officer and principal financial
officer, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control Over Financial Reporting. There have been no changes
in our internal control over financial reporting that occurred during the period
covered by this report that have materially affected, or are reasonably likely
to materially affect, our internal control over financial reporting.

                                        14







PART II  Other Information

ITEM 1.  Legal Proceedings

To avoid the cost and uncertainty of litigation, as of November 24, 2010, we
settled the lawsuit filed against us and others by CardioFocus. We paid
CardioFocus $175,000,entered into mutual releases and the lawsuit was dismissed.
This settlement expense was accrued and included in other expense for the year
ended September 30, 2010 and paid during the three months ended December 31,
2010.


Item 2.  Unregistered Sales of Equity Securities and Use of Proceeds
         None

Item 3.  Defaults Upon Senior Securities
         None

Item 4.  [Removed and Reserved]

Item 5.  Other Information
         None

Item 6.  Exhibits

(a)      Exhibits

 31.1     Certification pursuant to Section 302 of the Sarbanes-Oxley Act of
          2002 for Marvin P. Loeb
 31.2     Certification pursuant to Section 302 of the Sarbanes-Oxley Act of
          2002 for Jeffrey S. Rudner
 32.1     Chief Executive Officer Certification pursuant to 18 U.S.C. Section
          1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
          2002
 32.2     Principal Financial Officer Certification pursuant to 18 U.S.C.
          Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley
          Act of 2002


                                       15










                                 SIGNATURE PAGE

Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this Report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                             TRIMEDYNE, INC.

Date:  February 18, 2011                        /s/ Marvin P. Loeb
      -------------------                    -----------------------------------
                                             Marvin P. Loeb
                                             Chairman and
                                             Chief Executive Officer


Date:  February 18, 2011                        /s/ Jeffrey S. Rudner
      -------------------                    -----------------------------------
                                             Jeffrey S. Rudner
                                             Principal Financial Officer


                                       16